Study design
The exploratory and untargeted urinary peptidomic approach in this
study, was conducted to analyze the effect of GLP-1R agonist treatment
on the urinary peptidome of T2DM patients, as illustrated in Figure 1.
Briefly, urine samples from thirty-two T2DM patients collected at two
time points: pre-treatment and post-treatment, with a time interval of
11.5 ± 3.72 months in between were analyzed. Intervention with GLP-1R
agonist was introduced at 4.4 ± 4.11 months from pre-treatment visit and
the treatment duration until the post-treatment visit was 6.9 ± 3.59
months.